USFDA Warning Letter to Clinical Investigator at Bioequivalence Facility

Regulatory & Legal View source PDF Explain this filing

APLLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹830.00

prior close

₹820.00

announcement price

After-mkt

timing

Nifty Microcap 250market-1.0%+0.1% vs market

Pharmaceuticals peers, median of 166sector-0.2%-0.6% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.6

15m

-0.2

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-1.0+0.1-0.2-0.6

Next day

+2.7-0.4+3.1-0.3+3.0

+1.5-0.8+2.4-0.3+1.8

-0.6-1.9+1.3-1.3+0.8

+2.4-1.3+3.7-0.8+3.2

+0.4-1.0+1.3-0.7+1.1

-3.0-2.8-0.3-2.9-0.1

15d

-2.3+0.4-2.6-2.1-0.2

-0.6+2.4-3.0-0.9+0.3

-0.6+1.0-1.6-1.1+0.5

-4.8+1.8-6.6-2.6-2.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alembic Pharma informed that USFDA issued a Warning Letter on 10 Jul 2026 to a Clinical Investigator associated with a bioequivalence study at its Vadodara facility. The letter pertains to Informed Consent Form observations and not data integrity. Company says no restrictions on facility operations and no material financial impact identified. Coordinating with investigator to respond to USFDA within stipulated timeline.

Likely market impact

Negative regulatory signal, but limited direct impact as warning is to the investigator, not the facility. Data integrity not questioned. Watch response outcome.